MRS-1191

HY-124543			
185222-90-6			
C ₃₁ H ₂₇ NO ₄			
477.55			
Adenosine Receptor			
GPCR/G Protein			
Powder	-20°C	3 years	
	4°C	2 years	
In solvent	-80°C	2 years	
	-20°C	1 year	
	185222-90-1 C ₃₁ H ₂₇ NO ₄ 477.55 Adenosine I GPCR/G Pro Powder	185222-90-6 $C_{31}H_{27}NO_4$ 477.55 Adenosine Receptor GPCR/G Protein Powder -20°C 4°C In solvent -80°C	

R

MedChemExpress

SOLVENT & SOLUBILITY

Preparing Stock Solutio	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	2.0940 mL	10.4701 mL	20.9402 mL
		5 mM	0.4188 mL	2.0940 mL	4.1880 mL
		10 mM	0.2094 mL	1.0470 mL	2.0940 mL
	Please refer to the solubility information to select the appropriate solvent.				
ïvo		lubility information to select the app one by one: 10% DMSO >> 90% cor			

BIOLOGICAL ACTIVITY				
Description	MRS-1191 is a potent and selective A ₃ adenosine receptor antagonist with a K _B value of 92 nM, a K _i value of 31.4 nM for human A ₃ receptor and an IC ₅₀ of 120 nM for CHO cells ^[1] . MRS-1191 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.			
IC ₅₀ & Target	Ki: 31.4 nM (human A ₃ adenosine receptor) ^[1]			
In Vitro	The effects of putative A ₃ adenosine receptor antagonist of MRS-1191 is characterized in receptor binding and functional assays. MRS-1191 is found to be competitive in saturation binding studies using the agonist radioligand [¹²⁵ 1]AB-MECA (N ⁶ - (4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide) at cloned human brain A ₃ receptor expressed in HEK-293 cells. Antagonism is demonstrated in functional assays consisting of agonist-induced inhibition of adenylate cyclase and the stimulation of binding of [³⁵ S]guanosine 5'-O-(3-thiotriphosphate) ([³⁵ S]GTP-gamma-S) to the associated G-proteins. MRS-1191 with a K _B value of 92 nM, proves to be highly selective for human A ₃ receptor vs human A ₁ receptor-mediated effects on			

Product Data Sheet

0

N

0

Ö

C

adenylate cyclase^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Dis. 2023 Oct 28;14(10):706.
- Purinergic Signal. 2021 Oct 28.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jacobson KA, et al. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology. 1997 Sep;36(9):1157-65.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA